Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
about
Comparison of echinocandin antifungalsA novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen designEpidemiology of invasive candidiasis: a persistent public health problemIn vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Echinocandins: the newest class of antifungals.Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patientsPharmacokinetics and tissue distribution of anidulafungin in rats.Abdominal candidiasis is a hidden reservoir of echinocandin resistance.Pharmacokinetics and safety of intravitreal caspofungin.Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasisOnce-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaAntifungal pharmacokinetics and pharmacodynamicsPharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literaturePosaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Echinocandin antifungals: review and update.Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The echinocandins.Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths.The pharmacology and clinical use of caspofungin.Anidulafungin in the treatment of invasive fungal infections.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.A comparative evaluation of properties and clinical efficacy of the echinocandins.Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.Experiences with the use of caspofungin in paediatric patients.Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafunginImpact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolatesEvaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.Paradoxical echinocandin activity: a limited in vitro phenomenon?Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis.Tissue penetration of antifungal agents.
P2860
Q28273738-FF533CE0-B0A6-4C5A-8499-58A38C16724EQ28476705-35AD43D5-DE8E-4B10-AE86-B33B786A777EQ29616758-BE6C806D-6A09-4E4B-A503-80D5DA783101Q33876423-B9C1EFE9-B856-4901-956E-F22DF5E24B98Q34019188-FB9053C5-B546-4AD7-8427-8D815DC73A8AQ34045450-ED8FD24E-F13B-4C22-9DB5-B1667FBFFC49Q34591184-BF617325-B375-4A2A-8BE8-6A73C8B9FEC1Q34597421-A80F6335-E9E5-4729-9DB7-2C023C5AB4A2Q34597632-E2C25A54-A24A-4684-86DD-116DFBAA2A26Q34933267-E7E7847C-F490-4CEC-8D9B-E81936E7A3EAQ35065859-45EEF947-88D2-4503-A195-B9B629B6E952Q35105763-171DB016-D174-4E0F-ADF8-B82C39AB724BQ35127833-49E89D83-8C5C-42C4-A8C3-19EAFB22E5C4Q35647785-D75E7D97-4E81-431A-8560-C0D14A7AEE74Q35663841-FF267EC3-D1D5-4431-9468-90D7123E23A6Q35959484-84B0CF2C-959D-4458-9075-7E8A7D45D7D2Q36424973-4A6A8336-C916-44EB-BA67-DF33486BBF84Q36425025-36BB1AE8-F26A-4A06-921D-AB14ADAC2361Q36441524-DCA9009B-D955-4627-942B-9A8924DCD6A4Q36482785-C47BE232-9FE9-4A43-BD4E-92F237DC9812Q36505281-3E121967-AE51-4E89-91BB-4DD38AB22257Q36626518-A19A9E3A-3A62-4C7F-A270-BA51F2FC4674Q36742397-DD8205BD-43A6-4BFE-B847-D22A4DB6E982Q36785939-E223DB27-D2A0-4A98-AF7F-8CB217F36740Q36788428-2AF60BBB-B73B-4909-9352-4BB46257E51FQ36822941-F2E5F5B6-BDA2-4446-83FD-D1E096052683Q36845482-3BC3B166-C05F-44CA-8D65-60C51CBDA0E0Q36895839-AF40385A-4616-435B-881F-E4B2C0CF2729Q36924037-6E2EA7B9-0464-4315-8C43-B6AEDA949576Q36932989-2C03D7E0-3507-48B0-BF8C-26758F496944Q36949553-5D9A0A72-16D3-4232-94AC-A75443055912Q37015953-D76EFF8F-40AE-4779-BB2A-2149172023A7Q37159589-7348ED7E-1FBE-4FE0-9C31-48339D8C04E4Q37190801-7D0AFF99-448C-4509-9674-451BDF293DE7Q37263430-72B3DC6B-227E-47C9-BABE-7B5CF96FC145Q37291442-002B995F-B750-4E9B-925E-E892463DA7D5Q37320912-F7965A35-0EBB-4BCD-93AA-C8119480EA70Q37405284-91DBA7C1-9FB6-4E89-9C50-89C61A4137CAQ37449679-5013A259-869C-41FF-A7DA-F72B186BB8FBQ37544911-B3E858FC-6DDB-4E86-9518-17A4F18AFEDC
P2860
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacodynamics of caspofungi ...... o understanding drug activity.
@ast
Pharmacodynamics of caspofungi ...... o understanding drug activity.
@en
Pharmacodynamics of caspofungi ...... o understanding drug activity.
@nl
type
label
Pharmacodynamics of caspofungi ...... o understanding drug activity.
@ast
Pharmacodynamics of caspofungi ...... o understanding drug activity.
@en
Pharmacodynamics of caspofungi ...... o understanding drug activity.
@nl
prefLabel
Pharmacodynamics of caspofungi ...... o understanding drug activity.
@ast
Pharmacodynamics of caspofungi ...... o understanding drug activity.
@en
Pharmacodynamics of caspofungi ...... o understanding drug activity.
@nl
P2093
P2860
P1476
Pharmacodynamics of caspofungi ...... o understanding drug activity.
@en
P2093
Arnold Louie
George L Drusano
Mark Deziel
Michael F Drusano
Weiguo Liu
P2860
P304
P356
10.1128/AAC.49.12.5058-5068.2005
P407
P577
2005-12-01T00:00:00Z